CAT and prostate cancer: To study whether FOXO3a and catalase are involved in the DHT and R1881 inducing prostate cancer proliferation, LNCaP and 22RV1 cells were treated with different concentrations of DHT or R1881 and Enzalutamide for 48 h, and cell viability was evaluated by the CCK8 assay.